Patient adherence lever Adherium’s Hailie sensor technology and cloud platform deliver real-time medication usage data for inhaled therapies, offering a compelling proof point to partners and payers seeking to improve adherence and reduce COPD/asthma costs, presenting a ready pathway for integrated RPM offerings.

Expansive market footprint With over 170,000 devices sold across 30 countries and the widest US inhaler market coverage, there is a scalable opportunity to expand existing deployments, target new payer contracts, and extend distribution channels through strategic partners.

Reimbursement-ready The platform generates auditable reimbursement reports for payers and providers, and upcoming technology upgrades aim to access US reimbursement, creating a sales angle around financial ROI and reimbursement readiness for healthcare systems.

Clinical validation Backed by more than 85 studies involving 13,000 patients and proven to improve adherence and outcomes, Adherium can leverage clinical credibility to engage health systems, insurers, and employer-sponsored programs seeking evidence-based RPM solutions.

Strategic partnerships The company emphasizes collaboration with strategic partners to deliver new generation technology and value to payers and providers, presenting opportunities for co-sell arrangements, integration with existing EHR/clinical workflows, and joint market access initiatives.